• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

Research Briefing on [2-(2-isopropyl-1,3-thiazol-4-yl)ethyl]amine hydrochloride (CAS: 1269288-69-8)

This research briefing provides an updated overview of the latest scientific findings regarding the compound [2-(2-isopropyl-1,3-thiazol-4-yl)ethyl]amine hydrochloride (CAS: 1269288-69-8), a chemical entity of growing interest in medicinal chemistry and drug discovery. Recent studies have highlighted its potential as a versatile building block for the synthesis of biologically active molecules, particularly in the development of kinase inhibitors and antimicrobial agents.

The compound's structural features, including the thiazole ring and amine functionality, make it particularly valuable for creating molecular diversity in drug discovery programs. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility as a key intermediate in the synthesis of novel PI3K inhibitors, showing promising activity against various cancer cell lines. The hydrochloride salt form (1269288-69-8) offers improved solubility characteristics compared to the free base, enhancing its pharmaceutical applicability.

Recent synthetic methodology developments have focused on optimizing the production of [2-(2-isopropyl-1,3-thiazol-4-yl)ethyl]amine hydrochloride. A 2024 publication in Organic Process Research & Development described an improved synthetic route with higher yields (78% overall) and reduced environmental impact through green chemistry approaches. The process utilizes readily available starting materials and features a key thiazole ring formation step followed by reductive amination.

Pharmacological studies have revealed interesting structure-activity relationships for derivatives of this compound. Research published in Bioorganic & Medicinal Chemistry Letters (2023) identified that modifications at the isopropyl group and amine functionality significantly influence binding affinity to various biological targets. The hydrochloride salt form (1269288-69-8) was found to maintain excellent stability under standard storage conditions, with no significant degradation observed after 24 months at -20°C.

Current applications in drug discovery leverage this compound's ability to serve as a scaffold for diverse therapeutic targets. Several pharmaceutical companies have included derivatives in their pipelines for inflammatory diseases and oncology indications. The compound's favorable physicochemical properties, including a calculated logP of 1.2 and molecular weight of 206.72 g/mol, make it particularly attractive for lead optimization programs adhering to Lipinski's rule of five.

Future research directions are expected to explore the compound's potential in targeted protein degradation (PROTACs) and as a component of antibody-drug conjugates. Preliminary results from ongoing studies suggest that the thiazole moiety may contribute to improved cell permeability and target engagement. The scientific community continues to investigate novel synthetic applications and biological activities of this versatile building block in medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)